buy
price close busi juli
hub precis medicin
domin global leader next gener sequenc
instrument consum
biomed devic servic
growth slow time reacceler
unclear downgrad hold pt
follow big disappoint pre-announc miss provid addit
new color unfortun greater doubt see reacceler
growth variou unit admir increas concern
year dtc genet test return real growth ever ilmn abil
close complex popul genom contract ilmn abil close
acquisit pacbio push among challeng given lower growth
outlook mix pressur gross margin premium valuat downgrad
buy hold remov top pick list lower pt
new adj ep estim
move sidelin dont believ ultra-premium multipl
justifi compani look grow top bottom line
seem vulner larg miss what lack visibl
growth rate given wide rang move part would look get construct
concern prove transitori announc genom price
point would meaning acceler top line add headwind
gross oper net incom margin work hard drive cost
sequenc abl usher eagerli await genom
dtc troubl call illumina ceo franci desouza indic expect dtc
reacceler come year us doesnt impli recoveri
lower convict abil dtc genet test busi rev
bounc back within next year two perhap longer
complex popgen project introduc time risk reintroduc lumpi
risk busi increas concern ilmn abil close
complex popul genom contract govern deal expand
complex requir multipl stakehold sign concern shift
revenu recognit near term forward
deal get done note rise risk deal get done us ftc
longer uk phase review isnt clear might look like deal
result line pre-announc rev y/i
street model prior ilmn mid-juli
pre-announc result came ilmn origin guid due
expect revenu shortfal popul genom initi
shortfal array revenu due on-going weak dtc test
shortfal non-high-throughput sequenc system consum
lower revenue guid guid street consist pre-announc
miss lower revenue growth project disappoint y/i
guid revenue growth our/street prior
ratch ep guid drop adj ep guid
y/i undergo opex re-priorit off-set portion
guid seek better align invest dollar strateg prioriti
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
lower pt lower pt roll forward multipl
new adj ep estim
time global popul genom project appear illumina
control prior pre-announc result investor concern
compani guid revenu ramp vs popul
genom initi turn concern appropri recent ndr
meet indic good line sight global
program track would account ramp peg
sampl us million veteran program genom england
phase franc australia singapor four project indic us
pre-announc popul genom shortfal mostli due
instrument shortfal indic call larg pop miss
miss involv number stakehold isnt clear us involv
multipl govern and/or includ multipl pharma partner indic
permit disclos beyond seem logic initi
relat us uk franc singapor anoth initi plan
fulfil order later year manag indic fund issu
matter get signoff variou constitu stakehold expect
deal close wouldnt provid granular quarter
also indic even us us initi move along slowli
compani expect us-bas popul sequenc project move
along slowli expect lack visibl governments/stakehold
ous/emerg countri abl move faster deal highli complex
dtc mysteri meet manag recent specul
futur dtc custom could launch tier offer could
includ sequenc array weve specul year
believ want counter critic lack clinic util
health result need move sequenc health offer think
need address privaci concern think whether want
offer genet counsel line think correct may requir
addit develop regulatori time perhap year worth thu weve
view growth rate us dtc test risk continu believ
us dtc recoveri may occur instead may creat even
headwind hold-rat nasdaq
hold-rat labcorp lh nyse view said think temporari
slowdown array could partial forgiven beat high-margin sequenc
consum although sequenc consum grew
china concern china revenu declin y/i
grow concern return growth china given tariff concern
possibl competit concern believ bgi rel low threat
competit concern possibl could win one
larg popul genom project away
pacbio close date push grow concern ilmn abil
close propos acquisit pacbio deal spread continu widen
sinc illumina call addit question circul anti-
trust concern expect close acquisit pacbio
summer previous phase dialogu uk ftc
us peg chanc deal approv
segment guid guid revenu growth y/i
our/street also expect slightli sequenti
opex improv revenu lower revenue guid
impli guide-down due lower expect
dtc genet test longer ramp-up period pop seq project lower
expect sale non-high-throughput sequenc system consum part
due pharma partner program surmis bm push
expect sequenc revenue growth vs prior
mid-teen guid includ sequenc consum growth line
ilmn prior guid sequenc servic
hold buy target price juli
biomed devic servic
slightli y/i look declin expect
array revenu declin vs prior flat y/i guid expect
opex improv revenu
novaseq instrument/consum bright spot indic novaseq
consum volum grew y/i q/q driven strong interest
flow cell strip multi-system popul sequenc deal
miss june cutoff novaseq system shipment came ahead ilmn
expect note nextseq system consum grew sequenti
y/i average pull-through per nextseq system within target rang
annual continu expect novaseq pull-through per system
higher expect novaseq system shipment flat
slightli compar
model price target lower revenu estim
y/i y/i y/i y/i
lower adj ep estim y/i line
midpoint ilmn guid lower revenu ep forecast
y/i y/i initi revenu
adj ep estim y/i y/i lower
use multipl adj ep estim
hold buy target price juli
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
hold buy target price juli
biomed devic servic
hold buy target price juli
biomed devic servic
hold buy target price juli
biomed devic servic
hold buy target price juli
biomed devic servic
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin juli et
date time product juli et
price target appli multipl adj ep estim
laboratori corpor america hold lh
pt use multipl adj ep estim
pt use multipl revenu estim million discount back year plu net
risk achiev target price valuat
believ key risk includ major new product launch novaseq instrument premium valuat excess
peer group risk associ demand pace novaseq placement hiseq unit decommiss
competit noise/tract though believ meaning competit risk well bay nih/govern budgets/
spend particularli foreign govern like japan genom research center regulatori risk fda addit
risk factor less concern includ typic medic technolog risk price instrument consum risk
associ move test clinic increas compani focu bioinformat long-term also
highlight spend scale helix
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
regulatori risk exist new test indic delay denial approv would neg affect compani commerci risk
exist product reimburs competit continu weak economi could inhibit growth orasur drug
abus test busi risk associ intern sale infecti diseas product risk relat fund hiv
hold buy target price juli
biomed devic servic
particularli unit state competit risk gener hiv product dna genotek subsidiari larg
custom failur continu work would advers impact busi
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
